Impact of Ayurveda-based Panchkarma Therapy in Change of the VO2peak in Congestive Heart Failure Patients - An Observational Study
Published: 2024-02-28
Page: 34-41
Issue: 2024 - Volume 7 [Issue 1]
Rohit Sane
Madhavbaug Cardiac Clinic and Hospital, Thane, Maharashtra, India.
Pravin Ghadigaonkar
a Madhavbaug Cardiac Clinic and Hospital, Thane, Maharashtra, India.
Rahul Mandole *
Madhavbaug Cardiac Clinic, Dombivli East Manpada, Thane, Maharashtra, India.
Gurudatta Amin
Madhavbaug Cardiac Clinic and Hospital, Thane, Maharashtra, India.
Nilesh Kulthe
Madhavbaug Cardiac Clinic and Hospital, Central, UP, Karnataka and Goa, OPD, Kolhapur Region, Thane, Maharashtra, India.
Bipin Gond
Madhavbaug Cardiac Clinic and Hospital, Western and Marathwada, MP, Delhi Region, Thane, Maharashtra, India.
Sadik Khan
Madhavbaug Cardiac Clinics and Hospital, Pune and Vidarbha, Gujrat, West Bangal Region, Thane, Maharashtra, India.
*Author to whom correspondence should be addressed.
Abstract
Background and Aim: Reduced peak oxygen uptake (VO2peak) is a primary predictor of mortality in congestive heart failure (CHF) patients, and it is also an indicator of an individual's exercise capacity. Traditionally, exercise training during cardiac rehabilitation has been used to improve the patient's VO2peak. However, this may not apply to patients of all ages due to exercise intolerance. Therefore, this study focused on using ayurveda-based panchakarma treatment to increase maximal oxygen consumption during regular physical activities.
Methods: An observational study was conducted on 589 CHF patients who had opted for panchakarma treatment at various branches of Madhavbaug clinics. The patient's weight, body mass index (BMI), and blood pressure (BP) were measured before the start of the treatment. A 6-minute walk test (6MWT) and cardiac stress test with modified Bruce protocol were used to measure the initial VO2peak value for each patient. Using this value, the initial metabolic equivalent was calculated. The study population underwent a minimum of 7 sittings (twice a day) of panchakarma therapy for seven days. They were asked to follow up after 90 days. During the follow up, their weight, BMI, BP, VO2peak, and metabolic equivalent (MET) were measured and compared with the results of day 1.
Results: The study consisted of 589 CHF patients aged 20 to 90 years, of which 53.24% were males and 46.76% were females. There was a weight reduction (3.28 ± 1.24, p=0.0001), BMI (1.43 ± 0.5, p=0.0001), and blood pressure, and an increase in the VO2peak (8.18 ± 1.2, p=0.0001) and MET after the treatment. An age-wise comparison showed that the VO2 peak decreases with age and that the treatment's effect is seen more in younger patients. On the other hand, a similar improvement in oxygen consumption was seen in both genders. The treatment was also able to improve the VO2peak in patients with severe risk, i.e., those having an initial VO2peak value of <12mL/kg/min.
Conclusion: The ayurveda-based panchakarma treatment proved beneficial in improving the exercise capacity measured in VO2peak and MET, thus improving the exercise tolerance of the study population and reducing the risk of mortality.
Keywords: Panchkarma, VO2peak, metabolic equivalent, exercise capacity, congestive heart failure, cardiac output
How to Cite
References
Boback Ziaeian GCF. Epidemiology and etiology of heart failure. Nat Rev Cardiol. 2016;13(6):368–378.
Sarah A. Dick SE. Chronic heart failure and inflammation: What do we really know? Circ Res. 2016;119(1):159–76.
Strasser B, Burtscher M. Survival of the fittest: VO2max, a key predictor of longevity. Front Biosci (Landmark Ed). 2018;23(23):1505–16.
Inamdar AA, Inamdar AC. Heart failure: Diagnosis, management and utilization. J Clin Med. 2016;5(7):62.
Coelho-Ravagnani C de F, Melo FCL, Ravagnani FCP, Burini FHP, Burini RC. Estimation of the metabolic equivalent (met) of an exercise protocol based on indirect calorimetry. Rev Bras Med do Esporte. 2013;134–8.
Ann M, Swank, John Horton, Jerome L, Fleg Gregg C. Fonarow, Steven Keteyian, Lee Goldberg, Gene Wolfel et.al. Modest increase in peak VO2 Is related to better clinical outcomes in chronic heart failure patients. Circ Hear Fail. 2012;5:579–85.
De Maeyer C, Beckers P, Vrints CJ, Conraads VM. Exercise training in chronic heart failure. Ther Adv chronic Dis. 2013;4(3):105–17.
Sane Rohit MR. Efficacy of heart failure reversal treatment in patients with low ejection fraction. J Ayurveda Integr Med. 2018;9(4):285–9.
Sane R, Sugwekar V, Nadapude A, Hande A, Depe G, Mandole R. Study of efficacy of ischemia reversal program (IRP) in ischemic heart disease (IHD) patients with VO2max and Duke’s treadmill score. Int J Basic Clin Pharmacol; 2018.
Sane Rohit, Aklujkar Abhijeet, Patil Atul, Mandole R. Effect of heart failure reversal treatment as add-on therapy in patientswith chronic heart failure: A randomized, open-label study. Indian Hear Journal. 2017;69(3):299–304.
Jette M, Sidney K, Blumchen G. Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. Clin Cardiol.1990;13 :555–65.
Soni G. Physio-anatomical relation of Snehana & swedana with lymphatic system physio-anatomical relation of snehana & swedana with lymphatic system. Ayuhom. 2017;4(1):64–6.
Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. International Journal of Cardiology. 1995;49(3):191-9.
Maulik SK, Wilson V, Seth S, Bhargava B, Dua P, Ramakrishnan S, Katiyar CK. Clinical efficacy of water extract of stem bark of Terminaliaarjuna (Roxb. exDC.) Wight & Arn.in patients of chronic heart failure: A double-blind, randomized controlled trial. Phytomedicine; 2016.
Kim CH, Wheatley CM, Behnia M, Johnson BD. The effect of aging on relationships between lean body mass and VO2max in Rowers. PLoS One. 2016;11(8):e0160275.
Huldani Achmad H, Arsyad A, Putra AP, Sukmana BI, Adiputro DL et al. Differences in VO2 max based on age, gender, hemoglobin levels, and leukocyte counts in hajj prospective pilgrims in Hulu Sungai Tengah Regency, South Kalimantan. Syst Rev Pharm. 2020; 11(4):9–14.
Keteyian SJ, Brawner CA, Savage PD et al. Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Hear Journal. 2008;156(2):2 92-300.
Prathapan A, Vineetha VP, Raghu KG. Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS One. 2014;9 (4):e96220.
Kumar MS, Hiremath VS. Cardioprotective effect of Acorus calamus against doxorubicin-induced myocardial toxicity in albino Wistar rats. Indian Journal of Health Sciences and Biomedical Research (KLEU). 2016;9(2):225.
Gademan MG, van der Laarse A, Swenne CA, van der Wall EE. Oxygen uptake in heart failure: how much, how fast? Neth Heart J. 2009;17(6):224–5.